{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T09:35:49Z","timestamp":1767951349429,"version":"3.49.0"},"reference-count":22,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T00:00:00Z","timestamp":1765756800000},"content-version":"vor","delay-in-days":10,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Australian National Health and Medical Research Council (NHMRC) Clinical Trials Centre"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,1,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Patients with metastatic cancer are living longer due to treatment advances. We explored oncologists\u2019 perceptions about curability in metastatic cancer.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We invited medical oncologists to complete a 21-item online survey. We conducted descriptive analyses and thematically analyzed free-text responses.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 126 respondents completed the survey. The median age was 39\u2009years (range = 27-75). Most respondents worked in Australian (64%), metropolitan (88%), public practices (56%). The most frequently treated cancer types were breast (55%), lung (52%), and colorectal (50%). In total, 82% reported thinking that patients with metastatic cancer can be cured. Cancer types with the highest perceived chance of cure (median percentage) were testicular (81%), melanoma (32%), and colorectal (16%). At the time of diagnosis of metastatic cancer, 51% reported they would tell a patient that cure was possible. After treatment, 29% reported telling some patients they had been cured, whereas 74% reported telling some patients that they may have been cured. A higher proportion thought cure was a realistic possibility with immunotherapy (83%) rather than chemotherapy (40%), but only 44% and 27%, respectively, reported they would tell this to patients. In total, 46% reported discussing the possibility of cure more frequently with immunotherapy, 5% more frequently with chemotherapy, 7% as frequently with both, and 42% not discussing with either. Respondents identified oligometastatic disease, actionable mutations, and durable responses to immunotherapy as factors associated with cure.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Most respondents reported thinking that metastatic cancer is curable but were reluctant to tell individual patients with metastatic cancer they had been cured.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/jncics\/pkaf115","type":"journal-article","created":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T13:20:14Z","timestamp":1764768014000},"source":"Crossref","is-referenced-by-count":0,"title":["Curability of metastatic cancer: a survey of medical oncologists"],"prefix":"10.1093","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2138-8633","authenticated-orcid":false,"given":"Shalini","family":"Subramaniam","sequence":"first","affiliation":[{"name":"NHMRC Clinical Trials Centre, University of Sydney , Camperdown, NSW,","place":["Australia"]},{"name":"Bankstown-Lidcombe Hospital , Bankstown, NSW,","place":["Australia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8815-3551","authenticated-orcid":false,"given":"Kim Tam","family":"Bui","sequence":"additional","affiliation":[{"name":"Concord Cancer Centre , Concord, NSW,","place":["Australia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3793-8724","authenticated-orcid":false,"given":"Martin R","family":"Stockler","sequence":"additional","affiliation":[{"name":"NHMRC Clinical Trials Centre, University of Sydney , Camperdown, NSW,","place":["Australia"]},{"name":"Concord Cancer Centre , Concord, NSW,","place":["Australia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1662-3523","authenticated-orcid":false,"given":"Belinda E","family":"Kiely","sequence":"additional","affiliation":[{"name":"NHMRC Clinical Trials Centre, University of Sydney , Camperdown, NSW,","place":["Australia"]},{"name":"Concord Cancer Centre , Concord, NSW,","place":["Australia"]},{"name":"Macarthur Cancer Therapy Centre , Campbelltown, NSW,","place":["Australia"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2025,12,5]]},"reference":[{"key":"2026010902564554700_pkaf115-B1","doi-asserted-by":"publisher","first-page":"pkaa066","DOI":"10.1093\/jncics\/pkaa066","article-title":"When should oncologists use the words hope and cure?","volume":"4","author":"Kiely","year":"2020","journal-title":"JNCI Cancer Spectr"},{"key":"2026010902564554700_pkaf115-B2","author":"ASCO)"},{"key":"2026010902564554700_pkaf115-B3","doi-asserted-by":"publisher","first-page":"2251","DOI":"10.1093\/annonc\/mdu383","article-title":"Long-term survival, prevalence, and cure of cancer: a population-based estimation for 818 902 Italian patients and 26 cancer types","volume":"25","author":"Dal Maso","year":"2014","journal-title":"Ann Oncol"},{"key":"2026010902564554700_pkaf115-B4","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1007\/s40487-021-00163-3","article-title":"What is the definition of cure in non-small cell lung cancer?","volume":"9","author":"Morgan","year":"2021","journal-title":"Oncol Ther"},{"key":"2026010902564554700_pkaf115-B5","doi-asserted-by":"crossref","first-page":"38","DOI":"10.3747\/co.22.2287","article-title":"Use of the word \u201ccured\u201d for cancer patients\u2014implications for patients and physicians: the Siracusa Charter","volume":"22","author":"Tralongo","year":"2015","journal-title":"Curr Oncol"},{"key":"2026010902564554700_pkaf115-B6","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1016\/j.annonc.2020.04.478","article-title":"Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study","volume":"31","author":"Mok","year":"2020","journal-title":"Ann Oncol"},{"key":"2026010902564554700_pkaf115-B7","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1016\/j.annonc.2024.07.727","article-title":"Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 8-year follow-up results of efficacy and safety from the phase III CheckMate 214 trial","volume":"35","author":"Tannir","year":"2024","journal-title":"Ann Oncol"},{"key":"2026010902564554700_pkaf115-B8","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa2407417","article-title":"Final, 10-year outcomes with nivolumab plus ipilimumab in advanced melanoma","volume":"392","author":"Wolchok","year":"2025","journal-title":"N Engl J Med"},{"key":"2026010902564554700_pkaf115-B9","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/s1470-2045(19)30863-0","article-title":"Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study","volume":"21","author":"Swain","year":"2020","journal-title":"Lancet Oncol"},{"key":"2026010902564554700_pkaf115-B10","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1016\/S1470-2045(24)00735-6","article-title":"Ipilimumab plus nivolumab versus nivolumab alone in patients with melanoma brain metastases (ABC): 7-year follow-up of a multicentre, open-label, randomised, phase 2 study","volume":"26","author":"Long","year":"2025","journal-title":"Lancet Oncol"},{"key":"2026010902564554700_pkaf115-B11","doi-asserted-by":"publisher","first-page":"101221","DOI":"10.1016\/j.adro.2023.101221","article-title":"Is oligometastatic cancer curable? A survey of oncologist perspectives, decision making, and communication","volume":"8","author":"Cho","year":"2023","journal-title":"Adv Radiat Oncol"},{"key":"2026010902564554700_pkaf115-B12","doi-asserted-by":"crossref","first-page":"3684","DOI":"10.3390\/cancers12123684","article-title":"Living with metastatic cancer: a roadmap for future research","volume":"12","author":"Tometich","year":"2020","journal-title":"Cancers"},{"key":"2026010902564554700_pkaf115-B13","doi-asserted-by":"publisher","first-page":"3304","DOI":"10.1200\/jco.22.02212","article-title":"Evolving landscape of metastatic cancer survivorship: reconsidering clinical care, policy, and research priorities for the modern era","volume":"41","author":"Lai-Kwon","year":"2023","journal-title":"J Clin Oncol"},{"key":"2026010902564554700_pkaf115-B14","author":"Surveillance Research Program","year":"2025"},{"key":"2026010902564554700_pkaf115-B15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1136\/jitc-2021-003024","article-title":"Defining unique clinical hallmarks for immune checkpoint inhibitor-based therapies","volume":"10","author":"Michielin","year":"2022","journal-title":"J Immunother Cancer"},{"key":"2026010902564554700_pkaf115-B16","doi-asserted-by":"publisher","first-page":"3565","DOI":"10.1200\/JCO.2012.44.7821","article-title":"The median informs the message: accuracy of individualized scenarios for survival time based on oncologists\u2019 estimates","volume":"31","author":"Kiely","year":"2013","journal-title":"J Clin Oncol"},{"key":"2026010902564554700_pkaf115-B17"},{"key":"2026010902564554700_pkaf115-B18","doi-asserted-by":"publisher","first-page":"1616","DOI":"10.1056\/NEJMoa1204410","article-title":"Patients\u2019 expectations about effects of chemotherapy for advanced cancer","volume":"367","author":"Weeks","year":"2012","journal-title":"N Engl J Med"},{"key":"2026010902564554700_pkaf115-B19","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1111\/imj.16325","article-title":"Patients\u2019 perception of the benefits of palliative systemic therapy for advanced cancer","volume":"54","author":"Subramaniam","year":"2024","journal-title":"Intern Med J"},{"key":"2026010902564554700_pkaf115-B20","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1001\/jama.279.21.1709","article-title":"Relationship between cancer patients\u2019 predictions of prognosis and their treatment preferences","volume":"279","author":"Weeks","year":"1998","journal-title":"JAMA"},{"key":"2026010902564554700_pkaf115-B21","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1200\/op.20.00183","article-title":"Rallying cry from the place in between","volume":"16","author":"Spoozak","year":"2020","journal-title":"J Clin Oncol Oncol Pract"},{"key":"2026010902564554700_pkaf115-B22","doi-asserted-by":"publisher","first-page":"103728","DOI":"10.1016\/j.critrevonc.2022.103728","article-title":"Unmet supportive care needs of people with advanced cancer and their caregivers: a systematic scoping review","volume":"176","author":"Hart","year":"2022","journal-title":"Crit Rev Oncol Hematol"}],"container-title":["JNCI Cancer Spectrum"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jncics\/advance-article-pdf\/doi\/10.1093\/jncics\/pkaf115\/65881871\/pkaf115.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jncics\/article-pdf\/10\/1\/pkaf115\/65881871\/pkaf115.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jncics\/article-pdf\/10\/1\/pkaf115\/65881871\/pkaf115.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T07:56:55Z","timestamp":1767945415000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jncics\/article\/doi\/10.1093\/jncics\/pkaf115\/8379996"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,5]]},"references-count":22,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1,9]]}},"URL":"https:\/\/doi.org\/10.1093\/jncics\/pkaf115","relation":{},"ISSN":["2515-5091"],"issn-type":[{"value":"2515-5091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,2]]},"published":{"date-parts":[[2025,12,5]]},"article-number":"pkaf115"}}